Target intelligence / Profile preview

Baculoviral IAP repeat-containing protein 4 (XIAP)

Target
XIAP
Molecular classification
Enzyme, Other
01

Overview

Baculoviral IAP repeat-containing protein 4 (BIRC4), commonly known as X-linked inhibitor of apoptosis protein (XIAP), is a multi-functional protein that plays a central role in regulating cell death, inflammation, and immune signaling. As the most potent member of the inhibitor of apoptosis (IAP) family, BIRC4 directly binds and inhibits initiator caspase-9 and effector caspases-3 and -7 through its baculovirus IAP repeat (BIR) domains, thereby blocking both intrinsic and extrinsic apoptotic pathways. Additionally, its C-terminal RING domain possesses E3 ubiquitin ligase activity, which mediates the ubiquitination of target proteins, including caspases and RIPK2, to modulate NF-kappa-B and MAP kinase signaling pathways.

BIRC4 is frequently overexpressed in various human cancers, where it contributes to tumor cell survival, metastasis, and resistance to chemotherapy and radiation. Conversely, loss-of-function mutations in the BIRC4 gene cause X-linked lymphoproliferative syndrome type 2 (XLP-2), a rare immunodeficiency characterized by severe immune dysregulation, hemophagocytic lymphohistiocytosis (HLH), and inflammatory bowel disease. Therapeutic strategies targeting BIRC4 primarily involve small-molecule SMAC mimetics (such as xevinapant, tolinapant, and birinapant) that act as antagonists to disrupt caspase binding and promote apoptosis in cancer cells. In contrast, treatment for BIRC4 deficiency focuses on managing hyperinflammation, utilizing agents like the interleukin-18 inhibitor tadekinig alfa.

Other names
X-linked inhibitor of apoptosis proteinE3 ubiquitin-protein ligase XIAPInhibitor of apoptosis protein 3IAP-like protein 1hIAP-3hIAP3IAP3API3ILP1MIHAXLP2
02

Mechanism of action

IAP antagonism (SMAC mimetics) to prevent caspase inhibition and promote apoptosis in cancer cells; antisense-mediated knockdown of XIAP mRNA; or IL-18 inhibition (e.g., with Tadekinig alfa) to manage hyperinflammation in XIAP-deficient patients.

03

Biological functions

ApoptosisCell deathSignal transductionImmune responseCell proliferationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Cytokine release syndromeHepatotoxicityMyelosuppression (neutropenia, anemia, thrombocytopenia)Bell's palsyGastrointestinal toxicity (stomatitis, nausea, vomiting)FatigueHyperinflammation / Immune dysregulation
06

Interacting drugs

10 more in the full profile.

07

Biomarkers

XIAP expression level (mRNA or protein)cIAP1 degradationCaspase-3/7 activationTNF-alpha levelsIL-18 levelsFerritinC-reactive protein

Beyond the preview

Go deeper on Baculoviral IAP repeat-containing protein 4 (XIAP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baculoviral IAP repeat-containing protein 4 (XIAP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call